Takeda Pharmaceutical Company Completes Equity Issuance and Treasury Share Repurchase for Overseas Employees

TOKYO, Jul 08 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.F) completed the issuance of new shares and treasury share repurchase based on its Long Term Incentive Plan for overseas employees on July 08, 2026. Due to partial forfeiture, the number of newly issued shares was adjusted from the initial plan.

Originally scheduled to issue 16,989,076 ordinary shares, the company now plans to issue 16,877,109 shares. The total value of the transaction remains unchanged at ¥85.23 billion. The shares will be allocated to employees and subsidiaries of the company, totaling 10,477 individuals.

The changes resulted from some recipients losing their rights partially or entirely since the decision was made on June 09, 2026. According to the company, the impact on the current fiscal year's performance due to this adjustment is expected to be minor. Takeda continues to focus on developing innovative medicines across key therapeutic areas such as gastroenterology, inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

With headquarters in Japan, the company operates in approximately 80 countries worldwide, aiming to contribute to patients' quality of life through robust partnerships and diverse pipelines.